Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker APRE
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 28,100 | $0.89 | $25.0K Buy | Form 4 ↗ |
| Jan 30, 2026 | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | APRE Aprea Therapeutics, Inc. | Buy | 5,700 | $0.89 | $5,073 Buy | Form 4 ↗ |
| Dec 10, 2025 | Marc Duey Director | APRE Aprea Therapeutics, Inc. | Buy | 21,459 | $1.17 | $25.1K Buy | Form 4 ↗ |
| Dec 10, 2025 | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | APRE Aprea Therapeutics, Inc. | Buy | 5,000 | $1.17 | $5,850 Buy | Form 4 ↗ |
| Apr 3, 2025 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 2,497 | $1.80 | $4,495 Buy | Form 4 ↗ |
| Apr 3, 2025 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 3,003 | $1.87 | $5,616 Buy | Form 4 ↗ |
| Oct 23, 2024 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 500 | $3.92 | $1,960 Buy | Form 4 ↗ |
| Oct 18, 2024 | Marc Duey Director | APRE Aprea Therapeutics, Inc. | Sale | 6,462 | $4.58 | $29.6K Sale | Form 4 ↗ |
| Oct 16, 2024 | Marc Duey Director | APRE Aprea Therapeutics, Inc. | Buy | 30,000 | $4.39 | $131.7K Buy | Form 4 ↗ |
| Oct 15, 2024 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 250 | $2.90 | $725 Buy | Form 4 ↗ |
| Oct 14, 2024 | Marc Duey Director | APRE Aprea Therapeutics, Inc. | Buy | 190 | $2.58 | $490 Buy | Form 4 ↗ |
| Oct 14, 2024 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 1,000 | $2.59 | $2,590 Buy | Form 4 ↗ |
| Oct 11, 2024 | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | APRE Aprea Therapeutics, Inc. | Buy | 50 | $2.46 | $123 Buy | Form 4 ↗ |
| Oct 11, 2024 | Bernd R. Seizinger Director | APRE Aprea Therapeutics, Inc. | Buy | 10,000 | $2.68 | $26.8K Buy | Form 4 ↗ |
| Oct 10, 2024 | Oren Gilad President/CEO, Director | APRE Aprea Therapeutics, Inc. | Buy | 150 | $2.54 | $381 Buy | Form 4 ↗ |
| Oct 10, 2024 | John P. Hamill SrVP/CFO/Prin Fin & Acct Ofcr | APRE Aprea Therapeutics, Inc. | Buy | 450 | $2.61 | $1,175 Buy | Form 4 ↗ |
16 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:26 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances